Verve Therapeutics Inc (VERV)

$17.19 0.40 (2.27%)

16:00 EDT VERV Stock Quote Delayed 30 Minutes

7 CRISPR Stocks With the Best Long-Term Potential

By Alex Sirois Jan 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Why Is Verve Therapeutics (VERV) Stock Down 28% Today?

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

5 Top Stocks Cathie Wood Is Buying This Week

More Articles

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 368,693

Day's Range $17.15 - $17.83

52-Week Range $10.70 - $43.00

Dividend & Yield N/A (N/A)

VERV Stock Predictions, Articles, and Verve Therapeutics Inc News

From InvestorPlace
From the Web

The Top 5 Stocks Cathie Wood Is Buying This Week

By Eddie Pan, InvestorPlace Assistant News Writer Sep 23, 2022

Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys.

5 Top Stocks Cathie Wood Is Buying Right Now

By Eddie Pan, InvestorPlace Assistant News Writer Sep 19, 2022

Cathie Wood's ARKK is down over 50% YTD, although the fund manager is still continuing her purchases of high conviction companies.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

By William White, InvestorPlace Writer Jul 21, 2022

Good morning! We're starting off Thursday with an overview of the biggest pre-market stock movers traders need to know about!

Why These 3 Nasdaq Stocks Were Glowing Green This Week

From The Motley Fool May 11, 2023

These three biopharmaceutical stocks rocketed higher this week.

Verve stock spikes as Canaccord initiates with Buy (NASDAQ:VERV)

From Seeking Alpha Apr 13, 2023

Verve Therapeutics (VERV) added ~11% Thursday after Canaccord Genuity launched its coverage with a Buy rating and $29 per share target. Find out the reasons.

Verve Therapeutics GAAP EPS of -$0.67 beats by $0.09, revenue of $1.01M beats by $0.57M (NASDAQ:VERV)

From Seeking Alpha Mar 2, 2023

Verve Therapeutics press release (NASDAQ:VERV): Q4 GAAP EPS of -$0.67 beats by $0.09.Revenue of $1.01M beats by $0.57M.

Better Buy: Beam Therapeutics or Intellia Therapeutics?

From The Motley Fool Feb 22, 2023

The two clinical-stage gene-editing companies have good long-term prospects.

3 Deeply Undervalued Stocks That Could Double Your Money

From The Motley Fool Feb 15, 2023

These cutting-edge biotech stocks hold tremendous upside potential.

VERV stock drops as Goldman Sachs initiates with Sell (NASDAQ:VERV)

From Seeking Alpha Dec 15, 2022

Verve Therapeutics (VERV) lost ~10% in the morning hours Thursday after Goldman Sachs launched its coverage with a Sell rating and a $13 per share target. Read the full story here.